Tubulin is the target of many anticancer drugs, including N-phenyl-N'-(2-chloroethyl)urea (CEU). Unlike most anti-beta-tubulin agents, CEUs are protein monoalkylating agents binding through their N'-(2-chloroethyl)urea moiety to an amino acid nearby the colchicine-binding site on beta-tubulin isoform-2. Following the previously synthesized and attractive N-(3-omega-hydroxyalkylphenyl)-N'-(2-chloroethyl)urea
微管蛋白是许多抗癌药物的靶标,包括N-苯基-N'-(2-
氯乙基)
脲(CEU)。与大多数抗β-微管蛋白剂不同,CEU是蛋白质单烷基化剂,通过其N'-(2-
氯乙基)
脲部分与β-微管蛋白同种型2
秋水仙碱结合位点附近的
氨基酸结合。继先前合成和有吸引力的N-(3-ω-羟烷基苯基)-N'-(2-
氯乙基)
脲在纳摩尔
水平上表现出生长抑制活性后,我们研究了低级烷基和烷氧基对评估N-(3-ω-羟烷基苯基)
脲的重要性羟基化基团和链长对细胞生长的抑制作用及CEU的作用机理。在这里,我们描述了两个新系列的CEU的制备,并显示除ω-羟基化的1f以外,最有效的CEU衍
生物分别为2f和3e。